• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Phathom





































































Right now, the only reason I can find for the sell-off right is expected short-term losses: 320 reps cost a lot money, there will be a gap until sales are high enough for the company to make a profit. There might be additional dilution coming from stock issuance to fund the launch. Having said that, I've never seen such a sell-off on such good news. Product seems to be working extremely well in Japan so it's a matter of time stock goes up again.
 








Beware in WV: AH will be cancer in your business. Find anyone else to sell in that territory.

They need to rename this site gossip girl pharma….With so much competition in the industry how do people stay that are this petty. If AH was that bad the hiring managers will figure that out…

I’m not located in the near the snowshoe state district.

Please grow up to those of you that have nothing to say or do except be toxic and negative. I have no idea how people in this industry keep getting med sales jobs or leadership positions that are clearly so kooky.